Image
References
Image
  • 1.
    BMJ Open Diab Res Care 2019;7:e000654. doi:10.1136/bmjdrc-2019-000654
  • 2.
    JAMA, August 8, 2012—Vol 308, No. 6 Corrected on October 10, 2012
  • 3.
    J. Clin. Med. 2023, 12, 145. https://doi.org/10.3390/jcm12010145
  • 4.
    Fu AZ, et al. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy Diabetes Obes Metab. 2011;13(8):765–9.
  • 5.
    Correa ME Li V, Kum H-C et al. Assessing the Effect of Clinical Inertia on Diabetes Outcomes: a Modeling Approach. J Gen Intern Med
    2019;34:372-378.
  • 6.
    Paul SK, Klein K, Thorsted BL et al, Delay in treatment intensification the risks Of cardiovascular events in patients With type 2 diabetes, Cardiovasc
    Diabetol.2015;14:100
  • 7.
    Lind M, Imberg H, Coleman et Historical HbAlC, values may explain the type 2 diabetes legacy effect: UKPDS Diabetes Care. 2021;44(10):2231-2237.
  • 8.
    ADA, Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47
  • 9.
    Borgharkar SS,BMJ Open Diabetes Res Care. 2019 Jul 14;7(1):e000654.
  • 10.
    Reaven PD, et al. N Engl J Med. 2019 Jun 6;380(23):2215-2224.
  • 11.
    Aroda VR, et al. Diabetes Care. 2019;42(9):1724-1732.
  • 12.
    Gummesson A Diabetes Obes Metab. 2017 Sep;19(9):1295-1305.
  • 13.
    Pratley R et al. Lancet. 2019;394:39-50 16.
  • 14.
    Ryan DH, et al, Weight loss and improvement in comorbidity: differences at 5%, 10%, 15% and over. Curr Resp. 2017;6(2):187-94.
  • 15.
    Husain M, et al. N Engl J Med. 2019;381:841-851.
  • 16.
    Rybelsus®. Prescribing information. Novo Nordisk. 2023.
  • 17.
    Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients
    treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145. doi:10.3390/jcm12010145